Acute Leukemia

SITC is pleased to offer companion educational resources in support of the published Acute Leukemia CPG.

Webinar Recordings

• *Immunotherapy for the Treatment of Acute Leukemia- SITC CPG Webinar

• Practical Management Pearls for Immunotherapy for the Treatment of Acute Leukemia- SITC CPG Webinar

• Case Studies in Immunotherapy for the Treatment of Acute Leukemia- SITC CPG Webinar

Mini-Modules

• Antibody-Drug Conjugates
• CAR T Cell Therapy for ALL in Adults
• Sequencing Therapies

Breast Cancer

SITC is pleased to offer companion educational resources in support of the published Breast Cancer CPG.

Webinars

• *Immunotherapy for the Treatment of Breast Cancer Guideline Overview- SITC CPG Webinar

*This webinar has no external funding sources.

• Practical Management Pearls for Immunotherapy for the Treatment of Breast Cancer- SITC CPG Webinar

• Case Studies in Immunotherapy for the Treatment of Breast Cancer- SITC CPG Webinar

Mini-Modules

• First-Line Treatment of Metastatic TNBC
• Neoadjuvant and Adjuvant Treatment
• Toxicities and Adverse Events

Gastrointestinal Cancer
SITC is pleased to offer companion educational resources in support of the published Gastrointestinal Cancer CPG.

Webinars

• Practical Management Pearls for Immunotherapy for the Treatment of Gastrointestinal Cancer
• Case Studies in Immunotherapy for the Treatment of Gastrointestinal Cancer
  

Mini-Modules

• Immunotherapy biomarkers in the gastrointestinal tract
• Patient selection for immunotherapy for esophagogastric cancer

• Management of lower gastrointestinal tumors

Gynecologic Cancer
SITC is pleased to offer companion educational resources in support of the published Gynecologic Cancer CPG.

Webinars

• Practical Management Pearls for Immunotherapy for the Treatment of Gynecologic Cancer
• Case Studies in Immunotherapy for the Treatment of Gynecologic Cancer
  

Mini-Modules

• Immunotherapy biomarkers in the gynecologic tract: MMR, PD-L1, and TMB
• A case of vulvar melanoma
  
  

Head and Neck Cancer
SITC is pleased to offer companion educational resources in support of the published Head and Neck Cancer CPG.

Webinars

• *Immunotherapy for the Treatment of Squamous Cell Carcinoma of the Head and Neck (HNSCC)- SITC CPG Webinar

• Practical Management Pearls for Immunotherapy for the Treatment of Head and Neck Squamous Cell Carcinoma- SITC CPG Webinar

• Case Studies in Immunotherapy for the Treatment of Head and Neck Squamous Cell Carcinoma- SITC CPG Webinar

Mini-Modules

• Identifying Pseudoprogression and Managing Disease Unresponsive to Immunotherapy
• Risks and Benefits of Immunotherapy Combination Therapies to Treat Oligometastatic Disease
• Selecting Appropriate Treatment Strategies for Recurrent/Metastatic HNSCC

Hepatocellular Carcinoma

SITC is pleased to offer companion educational resources in support of the published Hepatocellular Carcinoma CPG.

Webinars

• *Immunotherapy for the Treatment of Hepatocellular Carcinoma Guideline Overview- SITC CPG Webinar

*This webinar has no external funding sources.

• Practical Management Pearls for Immunotherapy for the Treatment of Hepatocellular Carcinoma- SITC CPG Webinar

• Case Studies in Immunotherapy for the Treatment of Hepatocellular Carcinoma- SITC CPG Webinar

Mini-Modules

• Front-Line Management for Advanced HCC
• IO-IO Therapy in Second-Line Treatment
• Immunotherapy for HCC with Child-Pugh B Cirrhosis

Immune Checkpoint Inhibitor-related Adverse Events
SITC is pleased to offer companion educational resources in support of the published Immune Checkpoint Inhibitor-related Adverse Events CPG. 

Webinars

• *Immune Checkpoint Inhibitor-related Adverse Events- SITC CPG Webinar

• Practical Management Pearls for Immune Checkpoint Inhibitor-related Adverse Events

• Case Studies in Immune Checkpoint Inhibitor-related Adverse Events- SITC CPG Webinar

Mini-Modules

• Autoimmune Disease
• Special Patient Populations
• Vaccines and Chronic irAEs

Immune Effector Cell-related Adverse Events
SITC is pleased to offer companion educational resources in support of the published Immune Effector Cell-related Adverse Events CPG.

Webinars

• *Immune Effector Cell-related Adverse Events- SITC CPG Webinar

• Practical Management Pearls for Immune Effector Cell-related Adverse Events- SITC CPG Webinar

• Case Studies in Immune Effector Cell-related Adverse Events- SITC CPG Webinar

Mini-Modules

• CRS and HLH
• ICANS
• Product-specific Toxicity

Lung Cancer and Mesothelioma

SITC is pleased to offer companion educational resources in support of the published Lung Cancer and Mesothelioma CPG.

Webinars

• Practical Management Pearls for Immunotherapy for the Treatment of Lung Cancer and Mesothelioma- SITC CPG Webinar

• Case Studies in Immunotherapy for the Treatment of Lung Cancer and Mesothelioma- SITC CPG Webinar

Mini-Modules

• Immunotherapy for Lung Cancer in Challenging Populations
• Key Principles of Immune Related Adverse Events (irAEs)
• Managing Stage III Non-Small Cell Lung Cancer (NSCLC)

Lymphoma

SITC is pleased to offer companion educational resources in support of the published Lymphoma CPG.

Webinars

• *Immunotherapy for the Treatment of Lymphoma- SITC CPG Webinar

• Practical Management Pearls for Immunotherapy for the Treatment of Lymphoma- SITC CPG Webinar

• Case Studies in Immunotherapy for the Treatment of Lymphoma- SITC CPG Webinar

Mini-Modules

• Bispecifics
• CAR T
• Integration with Transplant

Melanoma

SITC is pleased to offer companion educational resources in support of the published Melanoma.

Webinars

• Practical Management Pearls for Immunotherapy for the Treatment of Melanoma
• Case Studies in Immunotherapy for the Treatment of Melanoma

Mini-Modules

• Treatment options for advanced melanoma
• Multidisciplinary care for resectable melanoma
• Management of melanoma brain metastases

Multiple Myeloma

SITC is pleased to offer companion educational resources in support of the published Multiple Myeloma CPG.

Webinars

• *Immunotherapy for the Treatment of Multiple Myeloma- SITC CPG Webinar
• Practical Management Pearls for Immunotherapy for the Treatment of Multiple Myeloma- SITC CPG Webinar

• Case Studies in Immunotherapy for the Treatment of Multiple Myeloma- SITC CPG Webinar

Mini-Modules

• Antibody-Drug Conjugates
• CAR T and Bispecifics
• Monoclonal Antibodies

Nonmelanoma Skin Cancer
SITC is pleased to offer companion educational resources in support of the published Nonmelanoma Skin Cancer CPG.

Webinars

• Practical Management Pearls for Immunotherapy for the Treatment of Nonmelanoma Skin Cancer- SITC CPG Webinar

• Case Studies in Immunotherapy for the Treatment of Nonmelanoma Skin Cancer- SITC CPG Webinar

Mini-Modules

• Immunotherapy in Challenging Populations in Non-Melanoma Skin Cancer
• New Developments in Neoadjuvant Therapy for Non-Melanoma Skin Cancers
• Overcoming Immune Evasion in Merkel Cell Carcinoma

Renal Cell Carcinoma

SITC is pleased to offer companion educational resources in support of the published Renal Cell Carcinoma CPG.

Webinars

• *Immunotherapy for the Treatment of Renal Cell Carcinoma- SITC CPG Webinar

• Practical Management Pearls for Immunotherapy for the Treatment of Renal Cell Carcinoma- SITC CPG Webinar

• Case Studies in Immunotherapy for the Treatment of Renal Cell Carcinoma- SITC CPG Webinar

Mini-Modules

• Management of Clear Cell RCC with Large Metastatic Burden
• Management of Toxicities
• Planning Immunotherapy Regimens for Challenging Patient Populations

Urothelial Cancer
SITC is pleased to offer companion educational resources in support of the published Urothelial Cancer CPG.

Webinars

• *Immunotherapy for the Treatment of Urothelial Cancer Guideline Overview- SITC CPG Webinar

*This webinar is supported, in part, by independent medical education grant funding from Amgen, AstraZeneca Pharmaceuticals LP and Merck & Co., Inc.

• Practical Management Pearls for Immunotherapy for the Treatment of Urothelial Cancer- SITC CPG Webinar

• Case Studies in Immunotherapy for the Treatment of Urothelial Cancer- SITC CPG Webinar

Mini-Modules

• Immune Irritability and Management of irAEs
• Management of High-Risk NMIBC
• Treatment of Unresectable Bladder Cancer